Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects

被引:114
作者
Bollag, RJ
Zhong, Q
Ding, KH
Phillips, P
Zhong, L
Qin, F
Cranford, J
Mulloy, AL
Cameron, R
Isales, CM
机构
[1] Med Coll Georgia, Inst Mol Med & Genet, Dept Med, Augusta, GA 30912 USA
[2] Augusta VAMC, Augusta, GA 30912 USA
关键词
GIP receptor; bone; bone mineral density; osteoporosis;
D O I
10.1016/S0303-7207(01)00405-1
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Glucose-dependent insulinotropic peptide (GIP) is a gut-derived hormone known to be important in modulating glucose-induced insulin secretion. In addition, GIP receptors are widely distributed and may have effects on multiple other tissues: fat cells, adrenal glands, endothelium and brain. We have demonstrated recently that GIP also has anabolic effects on bone-derived cells. We now demonstrate that GIP administration prevents the bone loss associated with ovariectomy. We propose that GIP plays a unique role in signaling the bone about nutrient availability, indicating the importance of the gut hormones in directing absorbed nutrients to the bone, and suggesting the concept of an 'entero-osseous axis'. Thus, GIP plays an integrative role helping coordinate efficient and targeted nutrient absorption and distribution. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:35 / 41
页数:7
相关论文
共 47 条
[1]   Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance [J].
Ahren, B ;
Larsson, H ;
Holst, JJ .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1997, 137 (02) :127-131
[2]   Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice [J].
Baggio, L ;
Kieffer, TJ ;
Drucker, DJ .
ENDOCRINOLOGY, 2000, 141 (10) :3703-3709
[3]  
Becker H D, 1978, Adv Exp Med Biol, V106, P105
[4]   Osteoblast-derived cells express functional glucose dependent insulinotropic peptide receptors [J].
Bollag, RJ ;
Zhong, Q ;
Phillips, P ;
Min, L ;
Zhong, L ;
Cameron, R ;
Mulloy, AL ;
Rasmussen, H ;
Qin, F ;
Ding, KH ;
Isales, CM .
ENDOCRINOLOGY, 2000, 141 (03) :1228-1235
[5]   Cushing's syndrome due to a gastric inhibitory polypeptide-dependent adrenal adenoma: Insights into hormonal control of adrenocortical tumorigenesis [J].
Chabre, O ;
Liakos, P ;
Vivier, J ;
Chaffanjon, P ;
Labat-Moleur, F ;
Martinie, M ;
Bottari, SP ;
Bachelot, I ;
Chambaz, EM ;
Defaye, G ;
Feige, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09) :3134-3143
[6]   Gastric inhibitory polypeptide (GIP) stimulates cortisol secretion, cAMP production and DNA synthesis in an adrenal adenoma responsible for food-dependent Cushing's syndrome. [J].
Chabre, O ;
Liakos, P ;
Vivier, J ;
Bottari, S ;
Bachelot, I ;
Chambaz, EM ;
Feige, JJ ;
Defaye, G .
ENDOCRINE RESEARCH, 1998, 24 (3-4) :851-856
[7]  
CHEN HK, 1995, J BONE MINER RES, V10, P1256
[8]   FAT-INDUCED JEJUNAL INHIBITION OF GASTRIC-ACID SECRETION AND RELEASE OF PANCREATIC GLUCAGON, ENTEROGLUCAGON, GASTRIC-INHIBITORY POLYPEPTIDE, AND VASOACTIVE INTESTINAL POLYPEPTIDE IN MAN [J].
CHRISTIANSEN, J ;
BECH, A ;
FAHRENKRUG, J ;
HOLST, JJ ;
LAURITSEN, K ;
MOODY, AJ ;
SCHAFFALITZKYDEMUCKADELL, O .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1979, 14 (02) :161-166
[9]  
CONVINEAU A, 1984, BIOCHEM BIOPH RES CO, V122, P283
[10]   Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats [J].
de Fonseca, FR ;
Navarro, M ;
Alvarez, E ;
Roncero, I ;
Chowen, JA ;
Maestre, O ;
Gómez, R ;
Muñoz, RM ;
Eng, J ;
Blázquez, E .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2000, 49 (06) :709-717